Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kraft Heinz Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Kraft Heinz Co trades at $24.69 (market cap $29.56B). The key difference: Kraft Heinz Co is far larger — about 34.2× Amphastar Pharmaceuticals Inc's market cap, and Kraft Heinz Co pays a 6.42% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KHC | |
|---|---|---|
Market Cap | $863.95M | $29.56B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $28.06 |
52-Week Low | $16.87 | $21.21 |
Enterprise Value | $1.26B | $45.88B |
Dividend Yield | — | 6.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Kraft Heinz (KHC) trades at $25.32, up 1.44% today, with a bearish technical signal but oversold RSI. The stock shows mixed fundamentals: earnings beat estimates in recent quarters, yet 2025 net income was -$5.85B, reflecting margin pressures. Revenue declined to $24.94B in 2025, while the P/E of 13.04 and P/B of 0.83 suggest undervaluation. Recent news highlights CEO Cahillane's strategy to boost marketing spend for growth, amid institutional selling by firms like Bank of America (Defense World, 2026-08-09).
Outlook remains cautious; the 6% dividend yield attracts income investors, but sustainability is questioned amid profit declines. Risks include persistent inflation and competitive headwinds. Analysts are mostly neutral (57.14% Hold), with a $24 consensus target, implying limited upside. The stock's trajectory hinges on successful execution of turnaround efforts to stabilize earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
